A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2019
Price : $35 *
At a glance
- Drugs Sapanisertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 20 Mar 2019 Status changed from active, no longer recruiting to completed.
- 02 Feb 2019 Planned End Date changed from 30 Jan 2019 to 28 Feb 2019.
- 21 Jan 2019 Planned End Date changed from 21 Dec 2018 to 30 Jan 2019.